Newsroom

Group picture
News
Mecklenburg-Western Pomerania's Minister of Science, Bettina Martin, announced today (July 31, 2023) in Greifswald 15 million euros of additional state funding for the construction of the Helmholtz Institute for One Health (HIOH). In the interim laboratories of the HIOH, in the presence of the Rector of the University of Greifswald, Prof Katharina Riedel, and the founding director of the Helmholtz Institute for One Health, Prof Fabian Leendertz, she informed about the extended state funding for the new construction of the research center.
31.07.2023
Helicobacter pylori, a pathogen residing in the stomach, is the cause of the most common chronic bacterial infection. ©HZI/Rohde
News
The constant rise in antimicrobial resistance (AMR) has a major impact on global public health, urgently requiring novel strategies to prevent and treat bacterial infections. The development of effective vaccines represents an attractive cost-effective alternative to novel antibiotics and would be a game changer for patients. For many bacterial infections, especially those occurring on mucosal sites, no effective vaccines exist. Helicobacter pylori (H. pylori), a pathogen residing in the stomach, is the cause of the most common chronic bacterial infection, affecting half of the world´s population, with a high risk to progress into gastric cancer. Therefore, among other gastrointestinal pathogens, H. pylori was declared as priority neglected AMR target pathogen by the WHO, requiring rapid intervention to counter AMR. Standard-of-care for H. pylori is still an antibiotic therapy combined with a proton pump inhibitor, and thus effective treatment of H. pylori infection is severely hampered by rising AMR.
24.07.2023
[Translate to English:]
News
The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct use in first-in-human clinical trials. Five projects—including two antimicrobial drug discovery projects of the German Center for Infection Research (DZIF)—are now being funded with a total of three million euros. One of the funded drug candidates was discovered and co-developed at the Helmholtz Centre for Infection Research (HZI) in Braunschweig.
19.07.2023
Picture of doctoral award winners
News
In his doctoral thesis at the Helmholtz Institute for RNA-based Infection Research (HIRI), Chunlei Jiao has paved the way for the development of the CRISPR-based RNA detection and recording platforms known as LEOPARD and TIGER. LEOPARD is a CRISPR-based method that is highly multiplexable, with the potential to detect a variety of disease-related biomarkers in just one test. On the other hand, TIGER enables the recording of transient cellular events at the single-cell level. The Helmholtz Association honors this outstanding achievement with the Doctoral Prize in the research field Health. The HIRI is a site of the Helmholtz Centre for Infection Research (HZI) in Braunschweig in cooperation with the Julius-Maximilians-Universität (JMU) Würzburg.
17.07.2023
Group picture
News
With numerous supporters, cooperation partners and companions, the Helmholtz Institute for RNA-based Infection Research (HIRI) Würzburg celebrated its groundbreaking ceremony today, July 6. The institute, a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) founded in 2017 in cooperation with the Julius-Maximilians-Universität (JMU) in the city on the River Main, will have its own building on the Würzburg medical campus. The project is being realized with funds from the Free State of Bavaria, represented by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy, and co-financed by the European Union.In his festive speech, Bavaria's Minister President Markus Söder emphasized the relevance of research funding for the Free State's strategy for the future.
06.07.2023
Photo of Prof Josef Penninger
News
From 1 July 2023, Professor Josef Penninger takes over the Scientific Management of the Helmholtz Centre for Infection Research (HZI). Penninger is internationally renowned for his outstanding contributions to genetic and molecular biology. Joining HZI from the University of British Columbia (Canada), where he had led the Life Sciences Institute, he starts his position as head of the interdisciplinary infection research center in Braunschweig. Penninger is taking over the role of Professor Dirk Heinz, who had led the research center since 2011.
27.06.2023

HZI in the media

University Bloomington (USA). Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

05.05.2025
|
Management & Krankenhaus

ermöglicht. Citrapeutics, ein Spin-off des Helmholtz-Zentrums für Infektionsforschung, entwickelt neuartige Immuntherapien gegen Krebs, die

05.05.2025
|
Bionity.COM

... des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg, einem Standort des Braunschweiger Helmholtz-Zentrums ...

02.05.2025
|
Bionity.COM

... und einen Molekularbiologen, der am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) an der Entwicklung ...

01.05.2025
|
Rotary Magazin

Prof. Rolf Müller is Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and ...

29.04.2025
|
Analytik NEWS

... zusammenarbeiten“, sagt Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrum für Infektionsforschung in ...

25.04.2025
|
T3N